[ CAS No. 20595-30-6 ] {[proInfo.proName]}

Name: 20595-30-6|trans-3-Fluorocinnamic acid|98%
Brand: Ambeed
SKU: A313110
Price: 8.0 USD
Availability: InStock
Rating: 90 (27 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

DV 2D 3D

3d Animation Molecule Structure of 20595-30-6

Structure of 20595-30-6 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 20595-30-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 20595-30-6 ]

SDS Specification

Alternatived Products of [ 20595-30-6 ]

Product Details of [ 20595-30-6 ]

CAS No. :	20595-30-6	MDL No. :	MFCD00004383
Formula :	C₉H₇FO₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	RTSIUKMGSDOSTI-SNAWJCMRSA-N
M.W :	166.15	Pubchem ID :	1551219
Synonyms :

Calculated chemistry of [ 20595-30-6 ]

Physicochemical Properties

Num. heavy atoms :	12
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.0
Num. rotatable bonds :	2
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	43.07
TPSA :	37.3 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.72 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.65
Log Po/w (XLOGP3) :	2.25
Log Po/w (WLOGP) :	2.23
Log Po/w (MLOGP) :	2.32
Log Po/w (SILICOS-IT) :	2.12
Consensus Log Po/w :	2.12

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.56

Water Solubility

Log S (ESOL) :	-2.53
Solubility :	0.495 mg/ml ; 0.00298 mol/l
Class :	Soluble
Log S (Ali) :	-2.67
Solubility :	0.356 mg/ml ; 0.00214 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-2.13
Solubility :	1.23 mg/ml ; 0.00738 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.79

Safety of [ 20595-30-6 ]

Signal Word:	Danger	Class:	6.1
Precautionary Statements:	P261-P301+P310-P305+P351+P338	UN#:	2811
Hazard Statements:	H301-H315-H319-H335	Packing Group:	Ⅲ
GHS Pictogram:

Application In Synthesis of [ 20595-30-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 20595-30-6 ]
Downstream synthetic route of [ 20595-30-6 ]

[ 20595-30-6 ] Synthesis Path-Upstream 1~10

1
[ 20595-30-6 ]
[ 700-84-5 ]

Reference： [1] Patent: WO2011/14613, 2011, A2,
[2] Patent: WO2012/35078, 2012, A1,
[3] Patent: US2014/45872, 2014, A1,

2
[ 20595-30-6 ]
[ 458-45-7 ]

Yield	Reaction Conditions	Operation in experiment
97%	With palladium 10% on activated carbon; hydrogen In ethanol for 2 h;	Step 1 (MZ-S1):3-fluorocinammic acid (20 g, 121 .9 mmol) was hydrogenated with 10percent Pd-C (2 g) in ethanolunder hydrogen pressure (7opsi) for 2h. The reaction mass was filtered through celite andwashed with ethanol. The filtrate was concentrated under reduced pressure to afford 19.5 g(97percent) of MZ-S1 as an off white solid, further used without any purification.

Reference： [1] Patent: WO2014/140279, 2014, A1, . Location in patent: Page/Page column 91; 177
[2] Patent: US2004/39014, 2004, A1,
[3] Bioorganic and Medicinal Chemistry Letters, 2000, vol. 10, # 14, p. 1519 - 1522
[4] Patent: US5486541, 1996, A,
[5] Patent: WO2008/85505, 2008, A1, . Location in patent: Page/Page column 83-84

3
[ 20595-30-6 ]
[ 458-45-7 ]

Reference： [1] Patent: WO2011/14613, 2011, A2, . Location in patent: Page/Page column 14; 15
[2] Patent: WO2012/35078, 2012, A1, . Location in patent: Page/Page column 181
[3] Patent: US2014/45872, 2014, A1, . Location in patent: Paragraph 1108

4
[ 20595-30-6 ]
[ 350-51-6 ]

Reference： [1] Journal of Organic Chemistry USSR (English Translation), 1979, vol. 15, p. 484 - 487[2] Zhurnal Organicheskoi Khimii, 1979, vol. 15, p. 545 - 549

5
[ 20595-30-6 ]
[ 456-88-2 ]

Reference： [1] Angewandte Chemie - International Edition, 2014, vol. 53, # 18, p. 4652 - 4656[2] Angew. Chem., 2014, vol. 126, # 18, p. 4740 - 4744,5
[3] Angewandte Chemie - International Edition, 2014, vol. 53, # 18, p. 4652 - 4656[4] Angew. Chem., 2014, vol. 126, # 18, p. 4740 - 4744,5

6
[ 20595-30-6 ]
[ 110117-84-5 ]

Reference： [1] Angewandte Chemie - International Edition, 2015, vol. 54, # 15, p. 4608 - 4611[2] Angew. Chem., 2015, vol. 127, # 15, p. 4691 - 4694,4

7
[ 456-88-2 ]
[ 723284-79-5 ]
[ 20595-30-6 ]
[ 110117-84-5 ]

Reference： [1] RSC Advances, 2016, vol. 6, # 61, p. 56412 - 56420

8
[ 20595-30-6 ]
[ 19883-77-3 ]
[ 110117-84-5 ]

Reference： [1] Angewandte Chemie - International Edition, 2014, vol. 53, # 18, p. 4652 - 4656[2] Angew. Chem., 2014, vol. 126, # 18, p. 4740 - 4744,5

9
[ 20595-30-6 ]
[ 19883-77-3 ]
[ 110117-84-5 ]

Reference： [1] Journal of the American Chemical Society, 2015, vol. 137, # 40, p. 12977 - 12983

10
[ 20595-30-6 ]
[ 723284-79-5 ]
[ 19883-77-3 ]
[ 110117-84-5 ]

Reference： [1] Journal of the American Chemical Society, 2015, vol. 137, # 40, p. 12977 - 12983

[ 20595-30-6 ] Synthesis Path-Downstream 1~88

1
[ 67-56-1 ]
[ 20595-30-6 ]
[ 74325-03-4 ]

Yield	Reaction Conditions	Operation in experiment
99%	With sulfuric acid; at 0℃;Reflux; Inert atmosphere;	Example 1; [0052] (/+/-)-Methyl 3-(3-fluorophenyl)acrylate (6). To a solution of (£)-3-(3- fluorophenyl)acrylic acid (5, 6.0 g, 32.7 mmol) in MeOH (150 mL) at 0 0C was added concentrated H2SO4 (3.0 mL) slowly. The reaction was heated under reflux for 24 h then cooled to room temperature and neutralized with Na2CO3 (1.0 g). The solvent was removed by rotary evaporation and the resulting yellow oil partitioned between EtOAc (300 mL) and saturated NaHCO3 (300 mL). The aqueous layer was extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with brine (200 mL) and dried over Na2SO4. The solvent was removed by rotary evaporation to yield 6 as a low melting (<;25C) white solid (32.0 mmol, 99%): 1R NMR (500 MHz, CDCl3) delta 3.79 (s, 3H), 6.39-6.43 (d, J= 16.0 Hz, IH), 7.04-7.07 (dt, J= 2.0, 8.0 Hz, IH), 7.18-7.20 (d, J= 9.0 Hz, IH), 7.25-7.26 (d, J= 8.0 Hz, IH), 7.30-7.35 (m, IH), 7.60-7.64 (d, J= 16.0 Hz, IH); 13C NMR (125 MHz, CDCl3) delta 52.0, 114.4, 114.6, 117.3, 117.4, 119.4, 124.29, 124.32, 130.6, 130.7, 136.8, 136.9, 143.6, 143.7, 162.2, 164.2, 167.2; LCQ-MS (M + H+) calcd for C10H10FO2 181, found 181.
	With thionyl chloride; at 0 - 20℃;	To a suspension of (2E)-3-(3-fluorophenyl)-2-propenoic acid (840 mg, 1 eq) in methanol (8 ml) at 00C was added thionyl chloride (0.443ml, 1.2 eq) dropwise. The reaction mixture was stirred at rt overnight. The reaction mixture was concentrated under reduced pressure to give 904 mg of product as a yellow liquid. MS (ES+) m/z 181 (MH+).
	With thionyl chloride; at 0 - 20℃;	To a suspension of (2E)-3-(3-fluorophenyl)-2-propenoic acid (840 mg, 1 eq) in methanol (8 ml) at 0 C was added thionyl chloride (0.443ml, 1.2 eq) dropwise. The reaction mixture was stirred at rt overnight. The reaction mixture was concentrated under reduced pressure to give 904 mg of product as a yellow liquid. MS (ES+) m/z 181 (MH+).

Reference： [1]Patent: WO2010/85749,2010,A2 .Location in patent: Page/Page column 22-23
[2]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 119 - 131
[3]Bulletin of the Academy of Sciences of the USSR Division of Chemical Science,1980,vol. 29,p. 437 - 442
Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya,1980,p. 619 - 625
[4]Bioorganic and Medicinal Chemistry,2004,vol. 12,p. 2021 - 2034
[5]Patent: WO2008/128962,2008,A1 .Location in patent: Page/Page column 63
[6]Patent: WO2009/141399,2009,A1 .Location in patent: Page/Page column 40

2
[ 5440-00-6 ]
[ 20595-30-6 ]
[ 1025813-84-6 ]

Reference： [1]Journal of Medicinal Chemistry,1993,vol. 36,p. 1333 - 1342

3
[ 81250-34-2 ]
[ 20595-30-6 ]
[ 1026960-58-6 ]

Reference： [1]Journal of Medicinal Chemistry,1993,vol. 36,p. 1333 - 1342

4
[ 20595-30-6 ]
[ 34576-84-6 ]

Reference： [1]Journal of Heterocyclic Chemistry,1990,vol. 27,p. 2047 - 2052

5
[ 20595-30-6 ]
[ 456-48-4 ]

Reference： [1]Tetrahedron,1994,vol. 50,p. 10933 - 10944
[2]Tetrahedron,1994,vol. 50,p. 10945 - 10954

6
[ 20595-30-6 ]
2,3-dibromo-3-(3-fluoro-phenyl)-propionic acid [ No CAS ]

Reference： [1]Physical Chemistry Chemical Physics,2005,vol. 7,p. 1966 - 1970

7
[ 20595-30-6 ]
[ 13565-05-4 ]

Yield	Reaction Conditions	Operation in experiment
100%	With thionyl chloride; In N,N-dimethyl-formamide; for 4h;Reflux;	General procedure: To a solution of 1.2 equiv of substituted cinnamic acid 1a-l (5 mmol) in 5 equiv of thionyl chloride(3.6 mL), a catalytic amount of DMF was added. The reaction mixture was refluxed for 4 h, andthen, solvent was evaporated under vacuum to get the product 2a-l in the form of a solid residue inquantitative yield. The solid residue was directly added partially to an ice-cold stirred solution of1.0 equiv of tert-butyl (2-aminoethyl)carbamate or tert-butyl (3-aminopropyl)carbamate and 2.0 equivtriethylamine in DCM (20 mL). After the addition, the mixture was warmed to room temperature andstirred for 2 h. Then, DCM (20 mL) was added and washed with 0.2 M HCl (40 mL), H2O (40 mL),5% saturated. NaHCO3 (40 mL) and brine (40 mL), then dried over anhydrous magnesium sulfate.The solvent was removed in vacuo to give the corresponding cinnamamide derivatives 3a-l (65%-75%,from 1a-l) and 4a-g (59%-70%, from 1a-g) as a white solid. 3a-l, 4a-g (4 mmol) in DCM/TFA(9:1, 40 mL) were stirred at room temperature for 1 h. Solvents were removed in vacuo to yield 5a-l(100%) and 6a-g (100%) as a colorless oil.
100%	With thionyl chloride; In dichloromethane; N,N-dimethyl-formamide;Reflux; Inert atmosphere;	General procedure: To a solution of appropriate substituted trans-cinnamic acid 2a-p (1 mmol) in dry dichloromethane the thionyl chloride (2 mmol)and a catalytic amount of DMF was added. The reaction mixturewas refluxed for 2-4 h under anhydrous conditions, the solventwas evaporated under vacuum to obtain corresponding substitutedcinnamoyl chlorides 3a-p which was further used for the next stepwithout further purification.
	With thionyl chloride;N,N-dimethyl-formamide; In chloroform; for 2.5h;Heating / reflux;	4.8 mL (90.3 mmol, 1.5 eq.) of thionyl chloride was added portionwise to a solution of 10 g (60.2 mmol) of 3-fluoro cinnamic acid in 44 mL of chloroform and 1 mL of DMF. The reaction was heated to reflux for 2.5 h. Then the solvents were distilled to to yield 11.4 g of the crude acid chloride, which was used without any further purifcation.

	With thionyl chloride; N,N-dimethyl-formamide; In chloroform; for 2.5h;Heating / reflux;	4.8 ml_ (90.3 mmol, 1.5 eq.) of thionyl chloride was added portionwise to a solution of 1O g (60.2 mmol) of 3-fluoro cinnamic acid in 44 ml_ of chloroform and 1 ml_ of DMF. The reaction was heated to reflux for 2.5 h. Then the solvents were distilled to to yield 11.4 g of the crude acid chloride, which was used without any further purifcation.The acid chloride was dissolved in 45 mL of acetone. At 0 0C 8.03 g of NaN3 (123.5 mmol, 2 eq.) were added portionwise. Then 41 mL of water were added while the temperature was kept below 5 C. The reaction was stirred for another 1.5 h. Then 55 mL of chloroform were added. The mixture was extracted with 80 mL of water followed by 40 mL of brine. After drying over Na2SO4 and filtration 14 mL of diphenyl ether were added and most of the chloroform was removed in vacuo (without heating). A total removal of the chloroform should be avoided.The solution containing the azide, diphenyl ether and the remaining chloroform was added dropwise at 260 0C within 15 minutes to a solution of 10 mL of tributyl amine in 97 mL of diphenyl ether. A vigorous reaction can be observed during the addition. The reaction was stirred for another 20 minutes at 260 0C. After cooling to room temperature 270 mL of n-heptane were added. The precipitated product was filtered off and washed with ether to yield 5.65 g of the title compound. MS (DCI) Detected mass: 164.0 (M+H+).
	With thionyl chloride;N,N-dimethyl-formamide; In chloroform; for 2.5h;Heating / reflux;	4.8 mL (90.3 mmol, 1.5 eq.) of thionyl chloride was added portionwise to a solution of 10 g (60.2 mmol) of 3-fluoro cinnamic acid in 44 ml of chloroform and 1 ml of DMF. The reaction was heated to reflux for 2.5 h. Then the solvents were distilled to to yield 11.4 g of the raw acid chloride, which was used without any further purifcation.
	With thionyl chloride; In chloroform; N,N-dimethyl-formamide; for 4h;Inert atmosphere; Reflux;	A cooled (0 C) solution of (E)-<strong>[20595-30-6]3-fluorocinnamic acid</strong> (1.66 g, 10.0 mmol) in CHCl3 (10 mL) was treated with SOCl2 (1.16 mL, 16.0 mmol, 1.6 equiv.), dropwise. Upon completion of addition, DMF (1 drop) was added, and the solution heated at reflux for 4 h. The solvent was removed in vacuo, the residue dissolved in Et2O (3 mL), and added dropwise to vigorously stirred 28% aq. NH4OH (30 mL). After stirring for 18 h, the mixture was partitioned between CH2Cl2 (100 mL) and H2O (100 mL). The organic layer was washed with H2O (2 × 200 mL), sat. aq. NaHCO3 (100 mL), dried (Na2SO4), and the solvent evaporated under reduced pressure to give 44 as a white crystalline solid (1.09 g, 66 %):
	With thionyl chloride; In dichloromethane; for 6h;Inert atmosphere; Reflux;	To a slurry of 3-fluorocinammic acid (2.0 g, 12 mmol) in dichloromethane (25 mL) was added thionyl chloride (1.8 mL, 24 mmol). The mixture was heated to reflux under a nitrogen atmosphere for 6 h. The solvents were removed in vacuo to give the acid chloride as a solid. A solution of (4S)-4-phenyl-l,3-oxazolidin-2-one (2.0 g, 12 mmol) in THF (20 mL) under an atmosphere of nitrogen was cooled to - 10 C in an ice-acetone bath. To the stirred solution was added nBuLi (4.8 mL of a 2.5 M solution in hexane, 12 mmol) dropwise over a period of 10 min. To this cold solution was added a solution of the acid chloride in 15 mL of THF dropwise over 10 min. The resulting solution was stirred at 0 C in an ice-water bath for 1 h. The reaction was quenched with the addition of aqueous NaHC(, and the mixture was extracted three times with EtOAc. The combined organic extracts were washed with water and brine, then dried (MgS04), filtered, and the solvent was removed in vacuo. The residue was chromatographed on a 80 g silica gel column using a gradient elution of 0-50% EtOAc:A, where A = 1 : 1 hexanes:CHCl3. Fractions containing product were combined and the solvents were removed in vacuo to give the title compound as a solid
	With oxalyl dichloride; N,N-dimethyl-formamide; In dichloromethane; for 1h;Reflux;	General procedure: To a solution of substituted cinnamic acid (1 mmol) in dichloromethane (DCM, 2 mL) were added oxalyl choride (0.5 mL) and a few drops of DMF at room temperature. Then the reaction was refluxed for 1h. After completion of the reaction, the liquid was removed under reduced pressure. The residue was dissolved with anhydrous DCM (10 mL) in flask under N2 protection and cooled in ice/water bath. Then 2-pyridylethylamine (1.5 mmol) and TEA (2 mmol) was added dropwise. After the reaction was completed by monitoring in TLC, water (10 mL) was added to the mixture then the aqueous phase was extracted with DCM (10 mL × 3). The combined organic layers were washed with brine, dried with anhydrous Na2SO4, filtered and concentrated. The residue was purified by chromatograph on silica gel (petroleum ether/acetone = 2/1, v/v) to give 1.
	With oxalyl dichloride; N,N-dimethyl-formamide; In tetrahydrofuran; at 0℃; for 0.5h;Inert atmosphere;	General procedure: Compound 1-4 (10 mmol, 2.5 g), ammonium chloride(10 mmol, 532 mg) and Fe (30 mmol, 1.67 g) were placed in adouble-neck flask, and 40 mL of THF and 8mL of H2Owere added tothe flask. The mixture was refluxed under nitrogen for 4 h. Whenthe reaction solution temperature cooled to room temperature,20 mL of H2O was added. The excess of Fe was filtered, and themixture was extracted with EtOAc (3 20 mL). The organic layerwas dried over anhydrous Na2SO4, filtered and concentrated toobtain the intermediate aminofuranone, which was used in thenext reaction without purification. The carboxylic acid (0.75 mmol)was added into a dry double-neck flask, and 5 mL of dry THF wasadded to the flask. N,N-Dimethylformamide (1.50 mmol, 0.15 mL)was added into the solution under nitrogen at 0 C. When thesewere completely dissolved, oxalyl chloride (3.75 mmol) was addedslowly. After 30 min, the solvent and excess oxalyl chloride werethen removed under reduced pressure to obtain an acyl chloride.The acyl chloride was kept dry. 100 mg of the intermediate aminofuranone was added into a dry double-neck flask, and 5 mL of dryTHFwas added to the flask. When these were completely dissolved,dry pyridine (1.06 mmol, 0.01 mL) was added under nitrogen at0 C. The THF solution of an acyl chloride (0.793 mmol) was addedinto the mixture slowly. After 30 min, 20 mL of saturated ammoniumchloride solution was slowly added into the mixture, and themixture was extracted three times with EtOAc (3 x 20 mL). Theorganic layer was dried over anhydrous Na2SO4, filtered andconcentrated to dryness, which was purified through silica gelcolumn (EA: PE 2: 1) to give A-1~A-7.
	With oxalyl dichloride; N,N-dimethyl-formamide; In dichloromethane; at 20℃; for 5h;Inert atmosphere;	General procedure: To a solution of cinnamic acid (1a01e24, 1a26e27, 1a29)(1.0 mmol) in dry CH2Cl2 was added oxalyl chloride (5.0 equiv) anda catalytic amount of DMF (0.01 equiv). The reaction mixture wasstirred at room temperature for 5 h before the solvent wasremoved. The residuewas dried under high vacuum and used in thenext step without further purification.

Reference： [1]Molecules,2016,vol. 21
[2]Bioorganic and Medicinal Chemistry,2017,vol. 25,p. 5726 - 5732
[3]Heterocycles,2006,vol. 70,p. 45 - 50
[4]Patent: WO2007/12421,2007,A1 .Location in patent: Page/Page column 40
[5]Patent: WO2008/77550,2008,A1 .Location in patent: Page/Page column 61
[6]Bioorganic and Medicinal Chemistry,2009,vol. 17,p. 2388 - 2399
[7]Patent: WO2007/12422,2007,A1 .Location in patent: Page/Page column 97
[8]Organic Letters,2011,vol. 13,p. 2544 - 2547
[9]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 6053 - 6058
[10]Journal of Medicinal Chemistry,2014,vol. 57,p. 5333 - 5347
[11]Patent: WO2015/13835,2015,A1 .Location in patent: Page/Page column 31
[12]New Journal of Chemistry,2016,vol. 40,p. 2433 - 2443
[13]Tetrahedron,2017,vol. 73,p. 204 - 211
[14]European Journal of Medicinal Chemistry,2017,vol. 127,p. 187 - 199
[15]Journal of Organic Chemistry,2017,vol. 82,p. 9627 - 9636
[16]Organic and Biomolecular Chemistry,2017,vol. 15,p. 9804 - 9808
[17]Drug Development Research,2019,vol. 80,p. 438 - 445
[18]European Journal of Medicinal Chemistry,2019,vol. 167,p. 414 - 425

8
[ 20595-30-6 ]
N-but-2-enyl-3-(3-fluoro-phenyl)-acrylamide [ No CAS ]

Reference： [1]Heterocycles,2006,vol. 70,p. 45 - 50

9
[ 20595-30-6 ]
N-but-2-enyl-N-[3-(3-fluoro-phenyl)-acryloyl]-acetamide [ No CAS ]

Reference： [1]Heterocycles,2006,vol. 70,p. 45 - 50

10
[ 20595-30-6 ]
dithiocarbonic acid S-[3-(acetyl-but-2-enyl-amino)-1-(3-fluoro-phenyl)-3-oxo-propyl] ester O-ethyl ester [ No CAS ]

Reference： [1]Heterocycles,2006,vol. 70,p. 45 - 50

11
[ 20595-30-6 ]
(2S,3S)-2-Azido-3-(3-fluoro-phenyl)-butyric acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 2533 - 2536

12
[ 20595-30-6 ]
(2S,3S)-2-Amino-3-(3-fluoro-phenyl)-1-((S)-3-fluoro-pyrrolidin-1-yl)-butan-1-one [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 2533 - 2536

13
[ 20595-30-6 ]
(2S,3S)-2-Azido-3-(3-fluoro-phenyl)-1-((S)-3-fluoro-pyrrolidin-1-yl)-butan-1-one [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 2533 - 2536

14
[ 20595-30-6 ]
(R)-3-[3-(3-Fluoro-phenyl)-butyryl]-4-phenyl-oxazolidin-2-one [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 2533 - 2536

15
[ 20595-30-6 ]
(R)-3-[(2R,3S)-2-Bromo-3-(3-fluoro-phenyl)-butyryl]-4-phenyl-oxazolidin-2-one [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 2533 - 2536

16
[ 20595-30-6 ]
(R)-3-[(2S,3S)-2-Azido-3-(3-fluoro-phenyl)-butyryl]-4-phenyl-oxazolidin-2-one [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 2533 - 2536

17
[ 20595-30-6 ]
[ 115665-70-8 ]

Reference： [1]Tetrahedron Letters,2009,vol. 50,p. 1834 - 1837
[2]Tetrahedron,2005,vol. 61,p. 4043 - 4052

18
[ 20595-30-6 ]
(1R,2S)-2-(3-Fluoro-phenyl)-cyclopropylamine [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2004,vol. 12,p. 2021 - 2034

19
[ 20595-30-6 ]
rac-trans-2-(3-fluorophenyl)-cyclopropanecarboxylic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2004,vol. 12,p. 2021 - 2034
[2]Organic and Biomolecular Chemistry,2016,vol. 14,p. 2498 - 2503

20
[ 20595-30-6 ]
(1S,2S)-2-(3-Fluoro-phenyl)-cyclopropanecarboxylic acid methyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2004,vol. 12,p. 2021 - 2034

21
[ 20595-30-6 ]
tert-butyl (2-(m-fluorophenyl)cyclopropyl)carbamate [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2004,vol. 12,p. 2021 - 2034
[2]Organic and Biomolecular Chemistry,2016,vol. 14,p. 2498 - 2503

22
[ 20595-30-6 ]
N⁶-[trans-2-(3-fluorophenyl)cyclopropyl]adenosine [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2004,vol. 12,p. 2021 - 2034

23
[ 20595-30-6 ]
[ 147700-10-5 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 1299 - 1310
[2]Journal of Medicinal Chemistry,1993,vol. 36,p. 1333 - 1342

24
[ 20595-30-6 ]
8-[(Z)-2-(3-Fluoro-phenyl)-vinyl]-1,3,7-trimethyl-3,7-dihydro-purine-2,6-dione [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 1299 - 1310

25
[ 20595-30-6 ]
(E)-3-(3-Fluoro-phenyl)-acryloyl azide [ No CAS ]

Reference： [1]Tetrahedron,2002,vol. 58,p. 5761 - 5766

26
[ 20595-30-6 ]
[ 425704-52-5 ]